While bispecific antibody therapies have the potential to improve outcomes for patients with relapsed/refractory follicular lymphoma (R/R FL), care teams practicing in the community setting face unique challenges to integrating these agents into individualized FL care. Tune in to this expert-led review of insights and lessons learned from an American Oncology Network quality improvement initiative. Discussions include key challenges in integrating bispecific antibodies into individualized FL treatment, and actionable plans to improve patient-centered care for patients with R/R FL.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/integrating-novel-classes-immunotherapy-into-treatment-paradigms-relapsed
- Start Date: 2024-05-03 05:00:00
- End Date: 2024-05-03 05:00:00
- Credit Details: IPCE Credits: 0.75 hours
AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Genentech (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest